Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Research & Development (2020 - 2025)

Xeris Biopharma Holdings' Research & Development history spans 6 years, with the latest figure at $7.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 29.25% year-over-year to $7.9 million, compared with a TTM value of $31.2 million through Dec 2025, up 21.93%, and an annual FY2025 reading of $31.2 million, up 21.93% over the prior year.
  • Research & Development for Q4 2025 was $7.9 million at Xeris Biopharma Holdings, up from $7.5 million in the prior quarter.
  • The five-year high for Research & Development was $10.1 million in Q4 2021, with the low at $3.7 million in Q2 2022.
  • Average Research & Development over 5 years is $6.3 million, with a median of $6.1 million recorded in 2022.
  • Year-over-year, Research & Development surged 97.3% in 2021 and then tumbled 50.85% in 2022.
  • Tracing XERS's Research & Development over 5 years: stood at $10.1 million in 2021, then tumbled by 50.85% to $5.0 million in 2022, then increased by 28.8% to $6.4 million in 2023, then fell by 4.54% to $6.1 million in 2024, then grew by 29.25% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Research & Development are $7.9 million (Q4 2025), $7.5 million (Q3 2025), and $8.1 million (Q2 2025).